<head><meta charset="UTF-8"></head><link href="../../style.css" rel="stylesheet"><p class="pubdate" >2021-02-28T11:51:07+00:00</p><p class="fly_title"  >肿瘤学</p><p class="title" >切中要害</p><p class="rubric"  >逐个研究癌症基因组中的基因可能启发更好的疗法</p><p>精准医学认为，每个人都是独特的，所以他们所患的疾病也是如此。它旨在针对个体患者的遗传和生物化学特征给出治疗方案。在肿瘤学领域，这就是“癌症依赖关系图”（Cancer Dependency Map，DepMap）要实现的目标，该项目由位于英国剑桥附近的惠康桑格研究所（Wellcome Sanger Institute）和美国麻省剑桥市的布罗德研究所（Broad Institute）联合研发。癌症是精准医学的一个上佳应用领域，这是因为癌症发生在先前规矩行事的细胞开始不受控地繁殖之时，通常是由于这些细胞的遗传密码发生了一个突变。大量突变都可能导致这种结果，因此可能有许多针对性的治疗方案。DepMap试图找到突变和对应的疗法。</p><p>布罗德研究所负责该项目的杰西·贝姆（Jesse Boehm）在上月的美国科学促进会（AAAS）会议上解释说，第一步是在实验室里培养癌细胞组织，方便研究人员观察分析。在DepMap启动之前已有约1700个实验室培养的癌细胞系。为增加这个数字，该项目的科学家求助于社交媒体。他们和美国的癌症慈善机构合作，鼓励全国各地的患者提交肿瘤活组织切片。这为他们提供了2000多个新样本，从中创建了400多个新细胞系。令人鼓舞的是，其中30%的癌症是罕见的或主要发生在儿童中——都是研究者需要更多样本的癌症种类。</p><p>一旦成功引导癌细胞在DepMap的培养皿中生长，下一步就是观察它们的弱点了。截至目前，研究小组已经针对500多种癌症测试了约6000种药物——相当于所有疾病已批准药物数目的一半。从中已经找到了一些有前景的候选药物。用于宠物关节炎的药物替泊沙林（Tepoxalin）似乎可以杀死ABCB1基因在其中过度活跃的癌症。治疗酒瘾的双硫仑（Disulfiram）似乎对某些缺乏与处理重金属相关的基因的肿瘤具有杀伤力。</p><p>新技术意味着不仅仅可以对药物做系统性分析。惠康桑格研究所的马修·加尼特（Matthew Garnett）讨论了使用CRISPR-CAS9对基因做同样的事。CRISPR-CAS9是细菌使用的一组化学剪刀，用于切碎和灭活由入侵它们的病毒引入的DNA。它被改造成通用DNA切割设备，已成为生物学最有用的工具之一。</p><p>切入重点</p><p>加尼特描述了惠康桑格的研究人员如何用CRISPR-CAS9令成百上千个癌细胞系中的几乎每个基因逐一失效。这使他们能够发现哪些基因对肿瘤的存活至关重要，从而可能成为有前景的新药的标靶。他以参与修复受损DNA的WRN基因为例。癌细胞常常已经缺乏DNA修复机制，有些似乎依赖WRN存活下去。加尼特说，基于这些观测结果，制药公司已经在研发旨在抑制WRN基因本身或其生成的蛋白质的药物。</p><p>解构癌细胞的基因组也带来了其他见解。贝姆博士指出，观察基因的表达速度（也就是制造蛋白质的速度）通常比在遗传密码中查找突变更能有效地预测脆弱性。他说，这对于某些儿童癌症尤其如此，这些癌症通常表现出极少的突变。</p><p>由此看来，这是一个令人鼓舞的开端。但还有很长的路要走。贝姆估计，尽管已经分析了约1000种不同类型的癌症的所有基因和数千种药物，但该项目尚有约九成未完成。这可能还是低估了。正如惠康桑格研究所的另一位DepMap研究员菲奥娜·贝汉（Fiona Behan）指出的那样，除了单独检测单个基因外，一次让多个基因失效可能也会带来有用的发现。但是，在那种情况下，可能的组合数量将是个天文数字。</p><p>而且，并不是所有培养皿中的结果都在人体上有效。哥伦比亚大学的安德里亚·卡利法诺（Andrea Califano）观察到，适应了实验室生长环境的癌细胞的基因表达模式往往与人体内生长的癌细胞不同。不过，正如加尼特在大会上所言，目前研发抗癌新药的成功率之低令人沮丧。如果DepMap能为新药研发人员找到合理的标靶，这可能会开始改变。</p><p class="line"  ></p><head><meta charset="UTF-8"></head><link href="../../style.css" rel="stylesheet"><p class="pubdate" >2021-02-28T11:51:07+00:00</p><p class="fly_title"  >Oncology</p><p class="title" >Precisely!</p><p class="rubric"  >Studying cancer genomes gene by gene could lead to better treatments</p><p>PRECISION MEDICINE holds that, because people are unique, so too are their diseases. It aims to prescribe treatments tailored to the genetic and biochemical characteristics of individual patients. Achieving this, in the context of oncology, is the purpose of the Cancer Dependency Map (DepMap), which is being developed jointly by the Wellcome Sanger Institute, near Cambridge, in Britain, and the Broad Institute in the city in Massachusetts of that name. Cancer is a good candidate for the application of precision medicine, because it arises when previously well-behaved cells start reproducing uncontrollably, usually as a result of a mutation in their genetic code. Numerous mutations can have this result, so many tailored treatments may be possible. DepMap seeks to find both mutations and treatments.</p><p>The first step, as Jesse Boehm, who runs the Broad’s side of the project, explained to last month’s AAAS meeting, is to grow cancerous tissue in laboratories, where it can be studied at researchers’ convenience. Before DepMap began, around 1,700 lines of lab-grown cancer cells were available. To try to increase this number, the project’s scientists turned to social media. Working with American cancer charities they encouraged patients across the country to send in biopsies of their tumours. That has given them more than 2,000 new samples, from which they have been able to create more than 400 extra cell lines. Encouragingly, 30% of these represent cancers that are either rare or occur mostly in children—both groups that researchers need more examples of.</p><p>Once the cancerous cells have been persuaded to start growing in DepMap's Petri dishes, the next step is to examine them for weaknesses. So far, the teams have tested around 6,000 drugs—about half the number ever licensed for any disease—against more than 500 cancers. They have already turned up some promising candidates. Tepoxalin, an arthritis medicine for pets, appears to kill cancers in which a gene called ABCB1 is overactive. Disulfiram, used to treat alcoholism, seems toxic to certain tumours that lack genes involved with the processing of heavy metals.</p><p>New technology means it is not only drugs which can be analysed systematically. Matthew Garnett, of the Sanger Institute, discussed using CRISPR-CAS9 to do the same for genes. CRISPR-CAS9 is a set of chemical scissors employed by bacteria to chop up and deactivate DNA introduced by viruses that prey on them. Repurposed as an all-purpose DNA-cutting device, it has become one of biology's most useful tools.</p><p>Cut to the chase</p><p>Dr Garnett described how researchers at the Sanger had used CRISPR-CAS9 to disable, one by one, nearly every gene in hundreds of cancer-cell lines. This permitted them to discover which genes are essential for a tumour's survival and might therefore make promising targets for new drugs. He gave the example of WRN, a gene involved in fixing damaged DNA. Cancer cells are often already deficient in DNA-repair mechanisms, and some seem reliant on WRN for survival. Based on those results, Dr Garnett said, drug companies are already developing drugs designed to suppress either WRN itself, or the protein it produces.</p><p>Deconstructing cancer cells’ genomes has yielded other insights, too. Dr Boehm noted that examining the rate at which genes are expressed—that is, used to make proteins—is often more useful for predicting vulnerabilities than looking for mutations in the genetic code. This, he said, is especially true of some childhood cancers, which often exhibit few mutations.</p><p>An encouraging start, then. But there is a long way to go. Dr Boehm estimated that, despite having analysed all the genes and thousands of drugs for around 1,000 different sorts of cancer, the project remains about 90% unfinished. This may be an underestimate. As Fiona Behan, another of the Sanger’s DepMap researchers, pointed out, besides examining individual genes in isolation, disabling several at once may also yield useful insights. In that case, though, the number of possible combinations would be astronomical.</p><p>Moreover, not all results in Petri dishes bear fruit in human beings. Andrea Califano of Columbia University observed that cancer cells which have adapted to grow in laboratories often have different patterns of gene expression from those that grow in bodies. Nevertheless, as Dr Garnett told the meeting, the success rate for developing new cancer drugs is, at the moment, depressingly low. If DepMap can uncover plausible targets for developers to aim at, that may start to change. ■</p><p class="line"  ></p><head><meta charset="UTF-8"></head><link href="../../style.css" rel="stylesheet"><p class="pubdate" >2021-02-28T11:51:07+00:00</p><p class="fly_title"  >腫瘤學</p><p class="title" >切中要害</p><p class="rubric"  >逐個研究癌症基因組中的基因可能啟發更好的療法</p><p>精準醫學認為，每個人都是獨特的，所以他們所患的疾病也是如此。它旨在針對個體患者的遺傳和生物化學特徵給出治療方案。在腫瘤學領域，這就是“癌症依賴關係圖”（Cancer Dependency Map，DepMap）要實現的目標，該項目由位於英國劍橋附近的惠康桑格研究所（Wellcome Sanger Institute）和美國麻省劍橋市的布羅德研究所（Broad Institute）聯合研發。癌症是精準醫學的一個上佳應用領域，這是因為癌症發生在先前規矩行事的細胞開始不受控地繁殖之時，通常是由於這些細胞的遺傳密碼發生了一個突變。大量突變都可能導致這種結果，因此可能有許多針對性的治療方案。DepMap試圖找到突變和對應的療法。</p><p>布羅德研究所負責該項目的傑西·貝姆（Jesse Boehm）在上月的美國科學促進會（AAAS）會議上解釋說，第一步是在實驗室里培養癌細胞組織，方便研究人員觀察分析。在DepMap啟動之前已有約1700個實驗室培養的癌細胞系。為增加這個數字，該項目的科學家求助於社交媒體。他們和美國的癌症慈善機構合作，鼓勵全國各地的患者提交腫瘤活組織切片。這為他們提供了2000多個新樣本，從中創建了400多個新細胞系。令人鼓舞的是，其中30%的癌症是罕見的或主要發生在兒童中——都是研究者需要更多樣本的癌症種類。</p><p>一旦成功引導癌細胞在DepMap的培養皿中生長，下一步就是觀察它們的弱點了。截至目前，研究小組已經針對500多種癌症測試了約6000種藥物——相當於所有疾病已批准藥物數目的一半。從中已經找到了一些有前景的候選藥物。用於寵物關節炎的藥物替泊沙林（Tepoxalin）似乎可以殺死ABCB1基因在其中過度活躍的癌症。治療酒癮的雙硫侖（Disulfiram）似乎對某些缺乏與處理重金屬相關的基因的腫瘤具有殺傷力。</p><p>新技術意味着不僅僅可以對藥物做系統性分析。惠康桑格研究所的馬修·加尼特（Matthew Garnett）討論了使用CRISPR-CAS9對基因做同樣的事。CRISPR-CAS9是細菌使用的一組化學剪刀，用於切碎和滅活由入侵它們的病毒引入的DNA。它被改造成通用DNA切割設備，已成為生物學最有用的工具之一。</p><p>切入重點</p><p>加尼特描述了惠康桑格的研究人員如何用CRISPR-CAS9令成百上千個癌細胞系中的幾乎每個基因逐一失效。這使他們能夠發現哪些基因對腫瘤的存活至關重要，從而可能成為有前景的新葯的標靶。他以參與修復受損DNA的WRN基因為例。癌細胞常常已經缺乏DNA修復機制，有些似乎依賴WRN存活下去。加尼特說，基於這些觀測結果，製藥公司已經在研發旨在抑制WRN基因本身或其生成的蛋白質的藥物。</p><p>解構癌細胞的基因組也帶來了其他見解。貝姆博士指出，觀察基因的表達速度（也就是製造蛋白質的速度）通常比在遺傳密碼中查找突變更能有效地預測脆弱性。他說，這對於某些兒童癌症尤其如此，這些癌症通常表現出極少的突變。</p><p>由此看來，這是一個令人鼓舞的開端。但還有很長的路要走。貝姆估計，儘管已經分析了約1000種不同類型的癌症的所有基因和數千種藥物，但該項目尚有約九成未完成。這可能還是低估了。正如惠康桑格研究所的另一位DepMap研究員菲奧娜·貝漢（Fiona Behan）指出的那樣，除了單獨檢測單個基因外，一次讓多個基因失效可能也會帶來有用的發現。但是，在那種情況下，可能的組合數量將是個天文數字。</p><p>而且，並不是所有培養皿中的結果都在人體上有效。哥倫比亞大學的安德里亞·卡利法諾（Andrea Califano）觀察到，適應了實驗室生長環境的癌細胞的基因表達模式往往與人體內生長的癌細胞不同。不過，正如加尼特在大會上所言，目前研發抗癌新葯的成功率之低令人沮喪。如果DepMap能為新葯研發人員找到合理的標靶，這可能會開始改變。</p><p class="line"  ></p>